Intensification therapy with autologous stem cell transplantation versus bortezomib-melphalan-prednisone for newly diagnosed multiple myeloma patients: A multicenter, phase III study of the european myeloma network (EMN02/HO95 MM trial)

Tacchetti P.; Beksac M.; Dimopoulos M.; Zamagni E.; Di Raimondo F.; Gay F.; Hajek R.; Marzocchi G.; Cellini C.; Mellqvist U.H.; Johnsen H.E.; Ludwig H.; Zweegman S.; Wester R.; Wu K.L.; Driessen C.; Troia R.; Cornelisse P.; Van Der Holt B.; Palumbo A.; Sonneveld P.

Intensification therapy with autologous stem cell transplantation versus bortezomib-melphalan-prednisone for newly diagnosed multiple myeloma patients: A multicenter, phase III study of the european myeloma network (EMN02/HO95 MM trial)

Tacchetti P., Beksac M., Dimopoulos M., Zamagni E., Di Raimondo F., Gay F., Hajek R., Marzocchi G., Cellini C., Mellqvist U.H., Johnsen H.E., Ludwig H., Zweegman S., Wester R., Wu K.L., Driessen C., Troia R., Cornelisse P., Van Der Holt B., Palumbo A.Sonneveld P.

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

The prospective, multicenter, phase III EMN02/HO95 MM trial was designed to randomly compare (R1) (1:1 ratio; stratification by ISS) four 42-day cycles of standard dose bortezomib-melphalan-prednisone (VMP) vs either a single or two sequential courses of melphalan 200 mg/m2 followed by autologous stem cell transplantation (ASCT), as intensification therapy for newly diagnosed multiple myeloma (MM) patients. A second randomization (R2) to consolidation therapy with bortezomib-lenalidomide-dexamethasone vs no consolidation was performed after intensification, to be followed by lenalidomide maintenance until progression or toxicity in both arms. A primary study end point was progression-free survival (PFS) from R1. From February 2011 to April 2014, 1510 patients aged

Original language	English
Pages (from-to)	26
Number of pages	1
Journal	Haematologica
Volume	102
Issue number	Supplement 3
Publication status	Published - 2017

Keywords

*autologous stem cell transplantation
*cancer size
*multiple myeloma
DNA polymorphism
adult
bortezomib
cancer staging
cancer survival
chromosome aberration
conference abstract
controlled study
diagnosis
drug therapy
female
follow up
genetic susceptibility
human
lenalidomide
major clinical study
male
melphalan
middle aged
multicenter study
overall survival
phase 3 clinical trial
probability
progression free survival
proportional hazards model
prospective study
randomization
randomized controlled trial
stratification
toxicity

Access to Document

Cite this

P., T., M., B., M., D., E., Z., F., D. R., F., G., R., H., G., M., C., C., U.H., M., H.E., J., H., L., S., Z., R., W., K.L., W., C., D., R., T., P., C., B., V. D. H., ... P., S. (2017). Intensification therapy with autologous stem cell transplantation versus bortezomib-melphalan-prednisone for newly diagnosed multiple myeloma patients: A multicenter, phase III study of the european myeloma network (EMN02/HO95 MM trial). Haematologica, 102(Supplement 3), 26. http://www.haematologica.org/content/102/s3/1.full.pdf+html http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emexa&NEWS=N&AN=620886261

@article{3ca3ac9bb2ee4fe0ae4e128587b42b26,

title = "Intensification therapy with autologous stem cell transplantation versus bortezomib-melphalan-prednisone for newly diagnosed multiple myeloma patients: A multicenter, phase III study of the european myeloma network (EMN02/HO95 MM trial)",

abstract = "The prospective, multicenter, phase III EMN02/HO95 MM trial was designed to randomly compare (R1) (1:1 ratio; stratification by ISS) four 42-day cycles of standard dose bortezomib-melphalan-prednisone (VMP) vs either a single or two sequential courses of melphalan 200 mg/m2 followed by autologous stem cell transplantation (ASCT), as intensification therapy for newly diagnosed multiple myeloma (MM) patients. A second randomization (R2) to consolidation therapy with bortezomib-lenalidomide-dexamethasone vs no consolidation was performed after intensification, to be followed by lenalidomide maintenance until progression or toxicity in both arms. A primary study end point was progression-free survival (PFS) from R1. From February 2011 to April 2014, 1510 patients aged",

keywords = "*autologous stem cell transplantation, *cancer size, *multiple myeloma, DNA polymorphism, adult, bortezomib, cancer staging, cancer survival, chromosome aberration, conference abstract, controlled study, diagnosis, drug therapy, female, follow up, genetic susceptibility, human, lenalidomide, major clinical study, male, melphalan, middle aged, multicenter study, overall survival, phase 3 clinical trial, probability, progression free survival, proportional hazards model, prospective study, randomization, randomized controlled trial, stratification, toxicity",

author = "Tacchetti P. and Beksac M. and Dimopoulos M. and Zamagni E. and F., {Di Raimondo} and Gay F. and Hajek R. and Marzocchi G. and Cellini C. and Mellqvist U.H. and Johnsen H.E. and Ludwig H. and Zweegman S. and Wester R. and Wu K.L. and Driessen C. and Troia R. and Cornelisse P. and B., {Van Der Holt} and Palumbo A. and Sonneveld P.",

year = "2017",

language = "English",

volume = "102",

pages = "26",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "Supplement 3",

}

P., T, M., B, M., D, E., Z, F., DR, F., G, R., H, G., M, C., C, U.H., M, H.E., J, H., L, S., Z, R., W, K.L., W, C., D, R., T, P., C, B., VDH, A., P & P., S 2017, 'Intensification therapy with autologous stem cell transplantation versus bortezomib-melphalan-prednisone for newly diagnosed multiple myeloma patients: A multicenter, phase III study of the european myeloma network (EMN02/HO95 MM trial)', Haematologica, vol. 102, no. Supplement 3, pp. 26. <http://www.haematologica.org/content/102/s3/1.full.pdf+html http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emexa&NEWS=N&AN=620886261>

Intensification therapy with autologous stem cell transplantation versus bortezomib-melphalan-prednisone for newly diagnosed multiple myeloma patients: A multicenter, phase III study of the european myeloma network (EMN02/HO95 MM trial). / P., Tacchetti; M., Beksac; M., Dimopoulos et al.
In: Haematologica, Vol. 102, No. Supplement 3, 2017, p. 26.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Intensification therapy with autologous stem cell transplantation versus bortezomib-melphalan-prednisone for newly diagnosed multiple myeloma patients: A multicenter, phase III study of the european myeloma network (EMN02/HO95 MM trial)

AU - P., Tacchetti

AU - M., Beksac

AU - M., Dimopoulos

AU - E., Zamagni

AU - F., Di Raimondo

AU - F., Gay

AU - R., Hajek

AU - G., Marzocchi

AU - C., Cellini

AU - U.H., Mellqvist

AU - H.E., Johnsen

AU - H., Ludwig

AU - S., Zweegman

AU - R., Wester

AU - K.L., Wu

AU - C., Driessen

AU - R., Troia

AU - P., Cornelisse

AU - B., Van Der Holt

AU - A., Palumbo

AU - P., Sonneveld

PY - 2017

Y1 - 2017

N2 - The prospective, multicenter, phase III EMN02/HO95 MM trial was designed to randomly compare (R1) (1:1 ratio; stratification by ISS) four 42-day cycles of standard dose bortezomib-melphalan-prednisone (VMP) vs either a single or two sequential courses of melphalan 200 mg/m2 followed by autologous stem cell transplantation (ASCT), as intensification therapy for newly diagnosed multiple myeloma (MM) patients. A second randomization (R2) to consolidation therapy with bortezomib-lenalidomide-dexamethasone vs no consolidation was performed after intensification, to be followed by lenalidomide maintenance until progression or toxicity in both arms. A primary study end point was progression-free survival (PFS) from R1. From February 2011 to April 2014, 1510 patients aged

AB - The prospective, multicenter, phase III EMN02/HO95 MM trial was designed to randomly compare (R1) (1:1 ratio; stratification by ISS) four 42-day cycles of standard dose bortezomib-melphalan-prednisone (VMP) vs either a single or two sequential courses of melphalan 200 mg/m2 followed by autologous stem cell transplantation (ASCT), as intensification therapy for newly diagnosed multiple myeloma (MM) patients. A second randomization (R2) to consolidation therapy with bortezomib-lenalidomide-dexamethasone vs no consolidation was performed after intensification, to be followed by lenalidomide maintenance until progression or toxicity in both arms. A primary study end point was progression-free survival (PFS) from R1. From February 2011 to April 2014, 1510 patients aged

KW - autologous stem cell transplantation

KW - cancer size

KW - multiple myeloma

KW - DNA polymorphism

KW - adult

KW - bortezomib

KW - cancer staging

KW - cancer survival

KW - chromosome aberration

KW - conference abstract

KW - controlled study

KW - diagnosis

KW - drug therapy

KW - female

KW - follow up

KW - genetic susceptibility

KW - human

KW - lenalidomide

KW - major clinical study

KW - male

KW - melphalan

KW - middle aged

KW - multicenter study

KW - overall survival

KW - phase 3 clinical trial

KW - probability

KW - progression free survival

KW - proportional hazards model

KW - prospective study

KW - randomization

KW - randomized controlled trial

KW - stratification

KW - toxicity

M3 - Article

SN - 0390-6078

VL - 102

SP - 26

JO - Haematologica

JF - Haematologica

IS - Supplement 3

ER -